{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/QTTB/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T01:23:07.352Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":11313,"canonical_name":"Q32 Bio Inc.","cik":"0001661998","uei":null,"lei":null,"duns":null,"ticker":"QTTB"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":42,"clinical":1},"count":43,"timeline":[{"ts":"2026-10-14","kind":"sec.filing","form_type":"4","title":"4 — Q32 Bio Inc. — 2026-10-14","url_slug":"/sec/cik-0001661998/4/0001193125-26-421835","accession_number":"0001193125-26-421835","importance":30},{"ts":"2026-10-09","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Q32 Bio Inc. — 2026-10-09","url_slug":"/sec/cik-0001661998/schedule-13g/0001231919-26-001441","accession_number":"0001231919-26-001441","importance":55},{"ts":"2026-09-30","kind":"sec.filing","form_type":"8-K","title":"8-K — Q32 Bio Inc. — 2026-09-30","url_slug":"/sec/cik-0001661998/8-k/0001193125-26-408435","accession_number":"0001193125-26-408435","importance":35},{"ts":"2026-09-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Q32 Bio Inc. — 2026-09-14","url_slug":"/sec/cik-0001661998/8-k/0001193125-26-389836","accession_number":"0001193125-26-389836","importance":35},{"ts":"2026-08-27","kind":"sec.filing","form_type":"4","title":"4 — Q32 Bio Inc. — 2026-08-27","url_slug":"/sec/cik-0001661998/4/0001193125-26-371291","accession_number":"0001193125-26-371291","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Q32 Bio Inc. — 2026-08-14","url_slug":"/sec/cik-0001661998/schedule-13g-a/0000919574-26-005207","accession_number":"0000919574-26-005207","importance":30},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Q32 Bio Inc. — 2026-08-05","url_slug":"/sec/cik-0001661998/10-q/0001193125-26-333831","accession_number":"0001193125-26-333831","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — Q32 Bio Inc. — 2026-08-05","url_slug":"/sec/cik-0001661998/8-k/0001193125-26-333813","accession_number":"0001193125-26-333813","importance":35},{"ts":"2026-07-28","kind":"sec.filing","form_type":"424B3","title":"424B3 — Q32 Bio Inc. — 2026-07-28","url_slug":"/sec/cik-0001661998/424b3/0001193125-26-321196","accession_number":"0001193125-26-321196","importance":30},{"ts":"2026-07-28","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Q32 Bio Inc. — 2026-07-28","url_slug":"/sec/cik-0001661998/effect/9999999995-26-002481","accession_number":"9999999995-26-002481","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"4/A","title":"4/A — Iwicki Mark T — 2026-07-21","url_slug":"/sec/cik-0001415537/4-a/0001193125-26-310978","accession_number":"0001193125-26-310978","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"4/A","title":"4/A — Q32 Bio Inc. — 2026-07-21","url_slug":"/sec/cik-0001661998/4-a/0001193125-26-310967","accession_number":"0001193125-26-310967","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"4/A","title":"4/A — Q32 Bio Inc. — 2026-07-21","url_slug":"/sec/cik-0001661998/4-a/0001193125-26-310970","accession_number":"0001193125-26-310970","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"4/A","title":"4/A — Q32 Bio Inc. — 2026-07-21","url_slug":"/sec/cik-0001661998/4-a/0001193125-26-310982","accession_number":"0001193125-26-310982","importance":30},{"ts":"2026-07-20","kind":"sec.filing","form_type":"4","title":"4 — Q32 Bio Inc. — 2026-07-20","url_slug":"/sec/cik-0001661998/4/0001193125-26-309331","accession_number":"0001193125-26-309331","importance":30},{"ts":"2026-07-17","kind":"sec.filing","form_type":"S-3","title":"S-3 — Q32 Bio Inc. — 2026-07-17","url_slug":"/sec/cik-0001661998/s-3/0001193125-26-307835","accession_number":"0001193125-26-307835","importance":30},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Kalowski Lee","title":"CFO and President","shares":53250,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Morrison Jodie Pope","title":"CEO","shares":132000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Violette Shelia M.","title":"Chief Scientific Officer","shares":37500,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Q32 Bio Inc. — 2026-07-15","url_slug":"/sec/cik-0001661998/8-k/0001193125-26-304964","accession_number":"0001193125-26-304964","importance":35},{"ts":"2026-07-15","kind":"sec.filing","form_type":"424B5","title":"424B5 — Q32 Bio Inc. — 2026-07-15","url_slug":"/sec/cik-0001661998/424b5/0001193125-26-304946","accession_number":"0001193125-26-304946","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Q32 Bio Inc. — 2026-07-13","url_slug":"/sec/cik-0001661998/8-k/0001193125-26-301464","accession_number":"0001193125-26-301464","importance":35},{"ts":"2026-07-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Q32 Bio Inc. — 2026-07-13","url_slug":"/sec/cik-0001661998/8-k/0001193125-26-301520","accession_number":"0001193125-26-301520","importance":35},{"ts":"2026-07-13","kind":"sec.filing","form_type":"424B5","title":"424B5 — Q32 Bio Inc. — 2026-07-13","url_slug":"/sec/cik-0001661998/424b5/0001193125-26-302100","accession_number":"0001193125-26-302100","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Q32 Bio Inc. — 2026-07-13","url_slug":"/sec/cik-0001661998/effect/9999999995-26-002273","accession_number":"9999999995-26-002273","importance":30},{"ts":"2026-07-10","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Q32 Bio Inc. — 2026-07-10","url_slug":"/sec/cik-0001661998/schedule-13g/0001213900-26-077181","accession_number":"0001213900-26-077181","importance":55},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Manke Isaac","title":null,"shares":53521,"price_per_share":2.8,"usd_value":149859,"security_title":"Common Stock","importance":15.1498588},{"ts":"2026-06-25","kind":"sec.filing","form_type":"S-3","title":"S-3 — Q32 Bio Inc. — 2026-06-25","url_slug":"/sec/cik-0001661998/s-3/0001193125-26-282783","accession_number":"0001193125-26-282783","importance":30},{"ts":"2026-06-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Q32 Bio Inc. — 2026-06-16","url_slug":"/sec/cik-0001661998/8-k/0001193125-26-272562","accession_number":"0001193125-26-272562","importance":35},{"ts":"2026-06-16","kind":"sec.filing","form_type":"4","title":"4 — Q32 Bio Inc. — 2026-06-16","url_slug":"/sec/cik-0001661998/4/0001193125-26-272692","accession_number":"0001193125-26-272692","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"3","title":"3 — Q32 Bio Inc. — 2026-06-08","url_slug":"/sec/cik-0001661998/3/0001231919-26-000606","accession_number":"0001231919-26-000606","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Q32 Bio Inc. — 2026-06-04","url_slug":"/sec/cik-0001661998/schedule-13g/0000921895-26-001559","accession_number":"0000921895-26-001559","importance":55},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Q32 Bio Inc. — 2026-06-01","url_slug":"/sec/cik-0001661998/4/0000947871-26-000594","accession_number":"0000947871-26-000594","importance":30},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"ORBIMED ADVISORS LLC","title":"","shares":1250000,"price_per_share":8,"usd_value":10000000,"security_title":"Common Stock","importance":60},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":1250000,"price_per_share":8,"usd_value":10000000,"security_title":"Common Stock","importance":60},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"OrbiMed Genesis GP LLC","title":"","shares":1250000,"price_per_share":8,"usd_value":10000000,"security_title":"Common Stock","importance":60},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"Xu Diyong","title":"","shares":1250000,"price_per_share":8,"usd_value":10000000,"security_title":"Common Stock","importance":60},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"ORBIMED ADVISORS LLC","title":"","shares":625000,"price_per_share":8,"usd_value":5000000,"security_title":"Common Stock","importance":55},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":625000,"price_per_share":8,"usd_value":5000000,"security_title":"Common Stock","importance":55},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"OrbiMed Genesis GP LLC","title":"","shares":625000,"price_per_share":8,"usd_value":5000000,"security_title":"Common Stock","importance":55},{"ts":"2026-05-28","kind":"sec.insider.p","reporter":"Xu Diyong","title":"","shares":625000,"price_per_share":8,"usd_value":5000000,"security_title":"Common Stock","importance":55},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Q32 Bio Inc. — 2026-05-15","url_slug":"/sec/cik-0001661998/schedule-13g/0000919574-26-003211","accession_number":"0000919574-26-003211","importance":55},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Q32 Bio Inc.","title":"A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06018428","excerpt":"[\"Alopecia Areata\"]","importance":45}]}